Bristol-Myers Squibb has been touted as a potential takeover target in the pharma industry – and potential buyers may take note of the continued strong performance of its cancer drug Opdivo
Allergan has said it is not interested in buying Shire after all, after announcing yesterday that it was considering a bid for the UK-listed firm also targeted by Takeda.
The FDA has granted ‘Breakthrough Therapy’ status for Roche’s Hemlibra (emicizumab) for people with haemophilia A without factor VIII inhibitors, as the Swiss firm aims to take market share